OCUMENSION-B: (I) PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME; AND (II) PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SCHEME
OCUMENSION-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
OCUMENSION-B: VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINTS ACHIEVED IN THE PHASE II CLINICAL TRIAL OF OT-202
OCUMENSION-B: DATE OF BOARD MEETING
OCUMENSION-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024
OCUMENSION-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
OCUMENSION-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
OCUMENSION-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: DISCLOSEABLE TRANSACTION DISPOSAL OF SHARES IN EYEPOINT PHARMACEUTICALS, INC.
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: Next Day Disclosure Return (Resubmission)
OCUMENSION-B: Next Day Disclosure Return (Resubmission)
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: Next Day Disclosure Return
OCUMENSION-B: Next Day Disclosure Return
No Data